Eat pray, love — or just eat more and weigh less
Published 10-DEC-2018 10:18 A.M.
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Eating as much as you want. For those who enjoy eating, that sounds like a great idea. Impractical, but somewhat useless if you are looking to maintain a healthy weight.
However, imagine being able to eat what you want and remain within a healthy weight range. That good news is the focus of this week’s biotech breakdown.
'Eat more, weigh less' may not be such an unattainable goal in future as it seems there is a gene that might allow you to eat as much as you want without gaining weight.
You can thank the mice for that... and perhaps leave a little extra cheese out for them when they come calling. Rest assured, they won’t put on weight.
The gene known as RCAN1 (aka you can eat one) was removed in mice. When they were fed, they failed to gain weight, even after gorging on high fat foods for prolonged periods.
The international team behind the study is hopeful a similar approach that inhibits this gene will also be effective with humans to combat obesity and serious diseases like diabetes.
The study is being led by Professor Damien Keating at Flinders University. It involved a huge genetic screen in rodents to identify novel genetic candidates that may cause obesity, potentially paving the way for new drug therapies.
“We know a lot of people struggle to lose weight or even control their weight for a number of different reasons. The findings in this study could mean developing a pill which would target the function of RCAN1 and may result in weight loss,” Keating says.
According to the OECD, obesity rates are set to increase. Obesity levels are expected to be particularly high in the United States, Mexico and England, where 47%, 39% and 35% of the population respectively are projected to be obese in 2030.
Australia is also in trouble, especially with childhood weight gain.
Obesity can lead to increased risk of serious diseases like type 2 diabetes, and heart disease, but avenues for effective therapeutic treatments are lacking.
There are two types of fat in the human body: brown fat burns energy, while white fat stores energy.
Keating says blocking RCAN1 helps to transform unhealthy white fat into healthy brown fat, presenting a potential treatment method in the fight against obesity.
“We have already developed a series of drugs that target the protein that this gene makes, and we are now in the process of testing them to see if they inhibit RCAN1 and whether they might represent potential new anti-obesity drugs.
“In light of our results, the drugs we are developing to target RCAN1 would burn more calories while people are resting. It means the body would store less fat without the need for a person to reduce food consumption or exercise more.
“We looked at a variety of different diets with various timespans from eight weeks up to six months, and in every case we saw health improvements in the absence of the RCAN1 gene.”
Further studies are required to determine if they translate the same results to humans.
“Our research is focused on understanding how cells send signals to each other and how this impacts health and the spread of disease.
“We really want to pursue this, it’s exciting and we have research funding from the Australian government through the National Health and Medical Research Council to continue to explore viable options. These results show we can potentially make a real difference in the fight again obesity.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.